SLIT2 underexpression in metastatic prostate cancer
US7968294B2 · kind B2 · utility
1Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 2009 |
| Grant date | Jun 28, 2011 |
| Priority date | — |
| Expiry date | Feb 18, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/136
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to SLIT2 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.